Global Hunter Reiterates Buy on BioSpecifics Technologies Corp. (BSTC)

Global Hunter is out with its report today on BioSpecifics Technologies Corp.

, reiterating Buy. In a note to clients, Global Hunter writes, "Our $32 fair value estimate is based on our DCF analysis that examines free cash flow through 2016. We believe there remains significant upside potential to our estimate and anticipate shares appreciating during the Xiaflex launch. We recommend BSTC shares based on our physician diligence, the company's long-term growth prospects, lack of competition, a de-risked clinical program, a solid balance sheet, upcoming milestones and favorable valuation. Upside to our fair value estimate could occur should the pace of drug and reimbursement adoption exceed Street expectations." Shares of BSTC closed Tuesday at $25.22, down 1.10% from Monday's close.